共 50 条
- [21] A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 AgentsMOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (03) : 221 - 225Masouri, SofiaStefanaki, IreneNtritsos, GiorgosKypreou, Katerina P.Drakaki, EleniEvangelou, EvangelosNicolaidou, ElectraStratigos, Alexandros JohnAntoniou, Christina
- [22] CNTO 1275 (anti-IL-12/23p40) treatment of psoriasis: Phase III trial resultsJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB122 - AB122Papp, KimYeilding, NewmanWang, YuhuaKimball, Alexa B.
- [23] A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 AgentsMolecular Diagnosis & Therapy, 2016, 20 : 221 - 225Sofia MasouriIrene StefanakiGiorgos NtritsosKaterina P. KypreouEleni DrakakiEvangelos EvangelouElectra NicolaidouAlexandros John StratigosChristina Antoniou
- [24] Administration of anti-IL-12 mAb in Crohn's disease patients leads to downmodulation of p40 expression and IL-12/IL-23 derived cytokinesGASTROENTEROLOGY, 2005, 128 (04) : A118 - A118Fuss, IJBecker, CYang, ZQGroden, CHornung, RNikolaev, AHeller, FNeurath, MStrober, WMannon, PJ
- [26] Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapyMEDICAL MYCOLOGY CASE REPORTS, 2021, 32 : 43 - 46Huang, Yun-HanMagleby, ReedRao, RemaWalsh, Thomas J.Singh, Harjot K.
- [27] Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibodyINFLAMMATORY BOWEL DISEASES, 2006, 12 (01) : 9 - 15Fuss, IJBecker, CYang, ZQGroden, CHornung, RLHeller, FNeurath, MFStrober, WMannon, PJ
- [28] Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitisEUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 828 : 26 - 30Takahashi, TakehiroKoga, YokoKainoh, Mie
- [29] New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel diseaseSCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (01) : 113 - 120Bravata, IvanaFiorino, GionataAllocca, MariangelaRepici, AlessandroDanese, Silvio
- [30] M480, AN ORAL FXR AGONIST, IS SUPERIOR TO CYCLOSPORINE A AND EQUALLY EFFICACIOUS AS ANTI-IL-12/23 IN THE ADOPTIVE TRANSFER MODEL OF IBD COLITISGASTROENTEROLOGY, 2018, 154 (06) : S198 - S199Liu, XueqingDedman, HarryO'Connell, RobertBendele, AlisonOhlsen, ConnorGovek, SteveNagasawa, JohnnyDouglas, KarensaMilik, AngelicaLu, NhinQian, JingOrtiz, AlvaroLee, Kyoung-JinSmith, NicholasWagner, BrandeeSong, Ken